These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2285498)

  • 41. Continuous veno-venous hemodiafiltration in methotrexate intoxication.
    Ziółkowska H; Kisiel A; Leszczyńska B; Bilska K; Jankowska K; Kuźma-Mroczkowska E; Stelmaszczyk-Emmel A; Woźniak W; Roszkowska-Blaim M
    Med Wieku Rozwoj; 2013; 17(4):347-54. PubMed ID: 24519778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant chemotherapy for osteogenic sarcoma.
    Etcubanas E; Wilbur JR
    Cancer Treat Rep; 1978 Feb; 62(2):283-7. PubMed ID: 346218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The biochemistry of the citrovorum factor rescue effect in normal bone marrow cells after high-dose methotrexate.
    Sauer H; Schalhorn A; Wilmanns W
    Eur J Cancer (1965); 1979 Oct; 15(10):1203-9. PubMed ID: 316389
    [No Abstract]   [Full Text] [Related]  

  • 44. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.
    Thomson AH; Daly M; Knepil J; Harden P; Symonds P
    Cancer Chemother Pharmacol; 1996; 38(6):566-70. PubMed ID: 8823500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.
    Zhang W; Zhang Q; Zheng TT; Zhen JC; Niu XH
    Chin Med J (Engl); 2016 Nov; 129(21):2530-2534. PubMed ID: 27779157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative administration of high-dose methotrexate for osteosarcoma.
    Chan KW; Knowling MA; Duncan CP; Morton KS
    Can J Surg; 1984 May; 27(3):305-7, 309. PubMed ID: 6586272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [(Management of acute toxicity after high dose methotrexate therapy)].
    Urban C; Mutz I; Kotz R; Krisch K
    Onkologie; 1979 Dec; 2(6):238-42. PubMed ID: 398013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma.
    Pratt CB; Howarth C; Ransom JL; Bowles D; Green AA; Kumar AP; Rivera G; Evans WE
    Cancer Treat Rep; 1980 Jan; 64(1):11-20. PubMed ID: 6966535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute bone marrow suppression and gastrointestinal toxicity following acute oral methotrexate overdose.
    Isoardi KZ; Harris K; Carmichael KE; Dimeski G; Chan BSH; Page CB
    Clin Toxicol (Phila); 2018 Dec; 56(12):1204-1206. PubMed ID: 29973099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The results of using high-dose methotrexate in treating osteogenic sarcoma].
    Perevodchikova NI; Eremina LA; Manziuk LV; Siniukov PA; Fedenko AN; Singin AS; Moldovanova LK
    Vopr Onkol; 1990; 36(6):667-71. PubMed ID: 2378085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Serum methotrexate determination by microbiological assay in patients receiving high-dosage methotrexate (author's transl)].
    Krisch K; Kotz D; Mehta BM
    Wien Klin Wochenschr; 1977 Jul; 89(14):479-81. PubMed ID: 268729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
    Jaffe N; Frei E; Watts H; Traggis D
    Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215
    [No Abstract]   [Full Text] [Related]  

  • 55. [EEG-slowing after high-dose Methotrexate with citrovorumfactor-rescue. A spectralanalytic study (author's transl)].
    Korinthenberg R; Lütkenhöner B; Palm D; Ritter J
    EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1982 Mar; 13(1):22-7. PubMed ID: 6806066
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.
    Pratt CB; Roberts D; Shanks EC; Warmath EL
    Cancer Res; 1974 Dec; 34(12):3326-31. PubMed ID: 4547680
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal.
    Boldy DA; Vale JA; Prescott LF
    Q J Med; 1986 Nov; 61(235):997-1002. PubMed ID: 3659250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.